Disease · MONDO_0005627
head and neck cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. head and neck cancer. Diseases, record MONDO_0005627. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005627
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of craniocervical region, cancer of head and neck, cancer of the head and neck, craniocervical region cancer, head and neck malignant neoplasia, head and neck neoplasm, head and neck tumours, head/neck neoplasm, malignant craniocervical region neoplasm, malignant head and neck neoplasm, malignant head and neck tumor, malignant head and neck tumour, malignant neoplasm of craniocervical region, malignant neoplasm of head and neck, malignant neoplasm of the head and neck, malignant tumor of head and neck, malignant tumor of the head and neck, malignant tumour of head and neck, malignant tumour of the head and neck
- Open Targets
Drugs215
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FLUOROURACIL | CHEMBL185 | Small molecule | Approval | PMDA | 26 | 25 | 25 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Approval | PMDA | 17 | 15 | 15 | Drugs and targets |
| AMIFOSTINE | CHEMBL1006 | Small molecule | Approval | DailyMed | 6 | 5 | 5 | Drugs and targets |
| GIMERACIL | CHEMBL1730601 | Small molecule | Approval | PMDA | 3 | 2 | 0 | Drugs and targets |
| TEGAFUR | CHEMBL20883 | Small molecule | Approval | PMDA | 3 | 2 | 0 | Drugs and targets |
| CETUXIMAB SAROTALOCAN | CHEMBL4298088 | Antibody drug conjugate | Approval | PMDA | 4 | 1 | 1 | Drugs and targets |
| NIMOTUZUMAB | CHEMBL2108359 | Antibody | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 67 | 67 | 67 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 44 | 44 | 44 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 34 | 34 | 34 | Drugs and targets |
1 to 10 of 215
See all 215 drugsTargets266
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 14 | Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 binding agent; Epidermal growth factor receptor erbB1 inhibitor | Approval | https://conductscience.org/library/genes/1956 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 13 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 10 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| TUBA1A | Tubulin | 9 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 9 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 9 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 9 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 9 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 9 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
| TUBB | Tubulin | 9 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/203068 | Drugs and targets |
1 to 10 of 266
See all 266 targetsTrials283
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00415194 | A Study for Patients With Head and Neck Cancer | Phase 3 | 795 | 2011-04-06 | Head and Neck Neoplasms | CISPLATIN, PEMETREXED | Its record names the disease | ClinicalTrials.gov |
| NCT00956007 | RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer | Phase 3 | 702 | 2024-05-28 | Head and Neck Cancer | CETUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | Phase 1/2 | 578 | 2022-04-12 | Various Advanced Cancer | DARATUMUMAB, IPILIMUMAB, NIVOLUMAB, RELATLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04428151 | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | Phase 2 | 408 | 2025-05-25 | Squamous Cell Carcinoma of Head and Neck | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01848834 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | Phase 1 | 297 | 2017-06-26 | Cancer, Solid Tumor | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00117572 | Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) | Phase 3 | 285 | 2018-04-09 | Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity | CISPLATIN, DOCETAXEL, FLUOROURACIL, HYDROXYUREA | Its record names the disease | ClinicalTrials.gov |
| NCT00088907 | Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer | Phase 3 | 270 | 2015-05-06 | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | DOCETAXEL, GEFITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03386721 | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | Phase 2 | 256 | 2023-02-21 | Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers | ATEZOLIZUMAB, SIMLUKAFUSP ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | Phase 2/3 | 196 | 2023-10-25 | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma of Unknown Primary, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | CETUXIMAB, DURVALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01976741 | Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) | Phase 1 | 168 | 2020-04-28 | Neoplasms | ROGARATINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 283
See all 283 trialsComparisons in its trials54
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pemetrexed/Cisplatin vs Placebo/Cisplatin: serious adverse events | 185 of 392 | 132 of 385 | 777 | NCT00415194 | Trial comparisons |
| IMRT vs IMRT Plus Cetuximab: deaths from any cause | 97 of 287 | 87 of 290 | 577 | NCT00956007 | Trial comparisons |
| IMRT vs IMRT Plus Cetuximab: serious adverse events | 50 of 282 | 83 of 276 | 558 | NCT00956007 | Trial comparisons |
| Induction Plus Chemoradiotherapy vs Chemoradiotherapy: deaths from any cause | 39 of 138 | 42 of 135 | 273 | NCT00117572 | Trial comparisons |
| Induction Plus Chemoradiotherapy vs Chemoradiotherapy: serious adverse events | 65 of 138 | 38 of 135 | 273 | NCT00117572 | Trial comparisons |
| IMRT + Cisplatin + Placebo vs IMRT + Cisplatin + Lapatinib: deaths from any cause | 23 of 64 | 26 of 63 | 127 | NCT01711658 | Trial comparisons |
| IMRT + Cisplatin + Placebo vs IMRT + Cisplatin + Lapatinib: serious adverse events | 26 of 59 | 31 of 60 | 119 | NCT01711658 | Trial comparisons |
| Panitumumab Plus Chemotherapy vs Chemotherapy Alone: serious adverse events | 34 of 56 | 27 of 55 | 111 | NCT00454779 | Trial comparisons |
| A: Cetuximab+FHX vs B: Cetuximab + PX: Objective Response Rate to CRT | 3 of 57 | 4 of 53 | 110 | NCT00468169 | Trial comparisons |
| A: Cetuximab+FHX vs B: Cetuximab + PX: deaths from any cause | 14 of 57 | 9 of 53 | 110 | NCT00468169 | Trial comparisons |
1 to 10 of 54
See all 54 comparisons in its trialsPapers from its trials108
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005627
GET https://conductscience.org/api/diseases/v1/MONDO_0005627/drugs?page=2